The epigenetics diagnostics market size has grown rapidly in recent years. It will grow from $16.56 billion in 2025 to $19.29 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to limited availability of epigenetic diagnostic tools, reliance on conventional molecular biology methods, growing awareness of epigenetic research, increasing academic and clinical research activities, slow adoption of automated instrumentation.
The epigenetics diagnostics market size is expected to see rapid growth in the next few years. It will grow to $35.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to technological advancements in sequencing and epigenetic analysis, rising investment in personalized medicine, expansion of oncology and metabolic disease diagnostics, integration of cloud-based bioinformatics services, increasing demand from pharmaceutical and biotechnology firms. Major trends in the forecast period include increasing adoption of epigenetic biomarker kits, rising use of next-generation sequencing and microarray systems, expansion of data analysis and bioinformatics services, growing focus on oncology and personalized medicine applications, integration of automated liquid handling and high-throughput platforms.
The increasing demand for personalized medicine is expected to drive the growth of the epigenetics diagnostics market in the coming years. Personalized medicine is an approach that tailors medical treatment to an individual’s genetic makeup, biology, and lifestyle factors. This demand is rising due to advancements in genetic and molecular profiling, which enable therapies customized to a person’s unique biological characteristics, improving treatment efficacy while reducing side effects. Epigenetics diagnostics supports personalized medicine by identifying individual epigenetic patterns, which inform customized prevention and treatment strategies for optimal patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine is propelling the expansion of the epigenetics diagnostics market.
Key players in the epigenetics diagnostics market are focusing on developing innovative approaches, such as clinical-grade epigenetic analysis, to improve the accuracy, sensitivity, and clinical utility of detecting disease-related epigenetic modifications. Clinical-grade epigenetic analysis involves using validated and standardized methods to detect epigenetic changes with the precision required for clinical diagnosis and treatment decisions. For instance, in October 2024, EpiMedTech, a Singapore-based biotechnology company, launched epiGeneComplete, a clinical-grade test combining genetic and epigenetic analysis via next-generation sequencing and advanced DNA methylation techniques. The test provides detailed insights into key health indicators, including aging, stress, inflammation, addiction risk, and metabolism. Conducted in CAP-accredited laboratories, this non-invasive saliva-based test offers high sensitivity and accuracy, supports personalized health profiling, and serves as an adaptable platform for future diagnostic expansion, representing a significant advancement in routine health screening and early disease detection.
In January 2023, Agilent Technologies Inc., a US-based biotechnology company, acquired Avida Biomed for an undisclosed amount. This acquisition aims to enhance Agilent’s product portfolio by providing advanced next-generation sequencing tools for clinical research and diagnostics, particularly to accelerate progress in precision oncology and cancer treatment. Avida Biomed, based in the US, specializes in epigenetics diagnostics, focusing on DNA methylation analysis for liquid biopsies.
Major companies operating in the epigenetics diagnostics market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GeneTex Inc., Bio-Techne Corporation, Promega Corporation, New England Biolabs Incorporated, Pacific Biosciences of California Inc., Enzo Biochem Inc., Diagenode Société Anonyme, Zymo Research Corporation, Active Motif Inc., ADmit Therapeutics SL, Epigentek Group Inc., INHERENT Biosciences Inc.
North America was the largest region in the epigenetics diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epigenetics diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the epigenetics diagnostics market by increasing the cost of imported instruments, reagents, and sequencing equipment. Segments such as next-generation sequencers, microarray systems, and PCR instruments are most impacted, particularly in regions like Asia-Pacific and Europe that rely on imports. This has led to higher operational costs for diagnostic laboratories and research institutes. On the positive side, tariffs have encouraged local manufacturing, development of domestic reagents, and investment in innovative assay platforms, fostering market resilience.
The epigenetics diagnostics market research report is one of a series of new reports that provides epigenetics diagnostics market statistics, including epigenetics diagnostics industry global market size, regional shares, competitors with a epigenetics diagnostics market share, detailed epigenetics diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics diagnostics industry. This epigenetics diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Epigenetic diagnostics refers to the scientific approach of detecting and analyzing modifications in gene activity - such as DNA methylation or histone alterations - that do not change the underlying DNA sequence but can significantly impact biological functions. This process focuses on identifying molecular changes to understand how they regulate gene expression and contribute to biological variability.
The primary products in epigenetic diagnostics include kits and reagents, software and services, and instruments. Kits and reagents are specialized tools for studying and analyzing epigenetic modifications such as DNA methylation, histone modifications, and chromatin interactions. These products employ technologies including DNA methylation analysis, histone methylation and acetylation, large noncoding RNA, microRNA modifications, and chromatin structure assessments. Applications span oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and more. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and clinical diagnostic laboratories.
The epigenetic diagnostics market consists of revenues earned by entities by providing services such as histone modification analysis, biomarker discovery, disease risk assessment, single-cell epigenetic analysis, longitudinal epigenetic monitoring, and DNA methylation profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic diagnostics market also includes sales of instruments, sample preparation tools, workflow control kits, and liquid biopsy assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The epigenetics diagnostics market size is expected to see rapid growth in the next few years. It will grow to $35.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to technological advancements in sequencing and epigenetic analysis, rising investment in personalized medicine, expansion of oncology and metabolic disease diagnostics, integration of cloud-based bioinformatics services, increasing demand from pharmaceutical and biotechnology firms. Major trends in the forecast period include increasing adoption of epigenetic biomarker kits, rising use of next-generation sequencing and microarray systems, expansion of data analysis and bioinformatics services, growing focus on oncology and personalized medicine applications, integration of automated liquid handling and high-throughput platforms.
The increasing demand for personalized medicine is expected to drive the growth of the epigenetics diagnostics market in the coming years. Personalized medicine is an approach that tailors medical treatment to an individual’s genetic makeup, biology, and lifestyle factors. This demand is rising due to advancements in genetic and molecular profiling, which enable therapies customized to a person’s unique biological characteristics, improving treatment efficacy while reducing side effects. Epigenetics diagnostics supports personalized medicine by identifying individual epigenetic patterns, which inform customized prevention and treatment strategies for optimal patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine is propelling the expansion of the epigenetics diagnostics market.
Key players in the epigenetics diagnostics market are focusing on developing innovative approaches, such as clinical-grade epigenetic analysis, to improve the accuracy, sensitivity, and clinical utility of detecting disease-related epigenetic modifications. Clinical-grade epigenetic analysis involves using validated and standardized methods to detect epigenetic changes with the precision required for clinical diagnosis and treatment decisions. For instance, in October 2024, EpiMedTech, a Singapore-based biotechnology company, launched epiGeneComplete, a clinical-grade test combining genetic and epigenetic analysis via next-generation sequencing and advanced DNA methylation techniques. The test provides detailed insights into key health indicators, including aging, stress, inflammation, addiction risk, and metabolism. Conducted in CAP-accredited laboratories, this non-invasive saliva-based test offers high sensitivity and accuracy, supports personalized health profiling, and serves as an adaptable platform for future diagnostic expansion, representing a significant advancement in routine health screening and early disease detection.
In January 2023, Agilent Technologies Inc., a US-based biotechnology company, acquired Avida Biomed for an undisclosed amount. This acquisition aims to enhance Agilent’s product portfolio by providing advanced next-generation sequencing tools for clinical research and diagnostics, particularly to accelerate progress in precision oncology and cancer treatment. Avida Biomed, based in the US, specializes in epigenetics diagnostics, focusing on DNA methylation analysis for liquid biopsies.
Major companies operating in the epigenetics diagnostics market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GeneTex Inc., Bio-Techne Corporation, Promega Corporation, New England Biolabs Incorporated, Pacific Biosciences of California Inc., Enzo Biochem Inc., Diagenode Société Anonyme, Zymo Research Corporation, Active Motif Inc., ADmit Therapeutics SL, Epigentek Group Inc., INHERENT Biosciences Inc.
North America was the largest region in the epigenetics diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epigenetics diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the epigenetics diagnostics market by increasing the cost of imported instruments, reagents, and sequencing equipment. Segments such as next-generation sequencers, microarray systems, and PCR instruments are most impacted, particularly in regions like Asia-Pacific and Europe that rely on imports. This has led to higher operational costs for diagnostic laboratories and research institutes. On the positive side, tariffs have encouraged local manufacturing, development of domestic reagents, and investment in innovative assay platforms, fostering market resilience.
The epigenetics diagnostics market research report is one of a series of new reports that provides epigenetics diagnostics market statistics, including epigenetics diagnostics industry global market size, regional shares, competitors with a epigenetics diagnostics market share, detailed epigenetics diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics diagnostics industry. This epigenetics diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Epigenetic diagnostics refers to the scientific approach of detecting and analyzing modifications in gene activity - such as DNA methylation or histone alterations - that do not change the underlying DNA sequence but can significantly impact biological functions. This process focuses on identifying molecular changes to understand how they regulate gene expression and contribute to biological variability.
The primary products in epigenetic diagnostics include kits and reagents, software and services, and instruments. Kits and reagents are specialized tools for studying and analyzing epigenetic modifications such as DNA methylation, histone modifications, and chromatin interactions. These products employ technologies including DNA methylation analysis, histone methylation and acetylation, large noncoding RNA, microRNA modifications, and chromatin structure assessments. Applications span oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and more. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and clinical diagnostic laboratories.
The epigenetic diagnostics market consists of revenues earned by entities by providing services such as histone modification analysis, biomarker discovery, disease risk assessment, single-cell epigenetic analysis, longitudinal epigenetic monitoring, and DNA methylation profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic diagnostics market also includes sales of instruments, sample preparation tools, workflow control kits, and liquid biopsy assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Epigenetics Diagnostics Market Characteristics
3. Epigenetics Diagnostics Market Supply Chain Analysis
4. Global Epigenetics Diagnostics Market Trends and Strategies
5. Epigenetics Diagnostics Market Analysis of End Use Industries
7. Global Epigenetics Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Epigenetics Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Epigenetics Diagnostics Market Segmentation
10. Epigenetics Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Epigenetics Diagnostics Market
12. China Epigenetics Diagnostics Market
13. India Epigenetics Diagnostics Market
14. Japan Epigenetics Diagnostics Market
15. Australia Epigenetics Diagnostics Market
16. Indonesia Epigenetics Diagnostics Market
17. South Korea Epigenetics Diagnostics Market
18. Taiwan Epigenetics Diagnostics Market
19. South East Asia Epigenetics Diagnostics Market
20. Western Europe Epigenetics Diagnostics Market
21. UK Epigenetics Diagnostics Market
22. Germany Epigenetics Diagnostics Market
23. France Epigenetics Diagnostics Market
24. Italy Epigenetics Diagnostics Market
25. Spain Epigenetics Diagnostics Market
26. Eastern Europe Epigenetics Diagnostics Market
27. Russia Epigenetics Diagnostics Market
28. North America Epigenetics Diagnostics Market
29. USA Epigenetics Diagnostics Market
30. Canada Epigenetics Diagnostics Market
31. South America Epigenetics Diagnostics Market
32. Brazil Epigenetics Diagnostics Market
33. Middle East Epigenetics Diagnostics Market
34. Africa Epigenetics Diagnostics Market
36. Epigenetics Diagnostics Market Competitive Landscape and Company Profiles
37. Epigenetics Diagnostics Market Other Major and Innovative Companies
40. Epigenetics Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Epigenetics Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses epigenetics diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for epigenetics diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The epigenetics diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Kits And Reagents; Software And Services; Instruments2) By Technology: Deoxyribonucleic Acid (DNA) Methylation; Histone Methylation; Histone Acetylation; Large NonCoding; Ribonucleic Acid (RNA); Micro Ribonucleic Acid (RNA) Modification; Chromatin Structures
3) By Application: Oncology; Metabolic Diseases; Developmental Biology; Immunology; Cardiovascular Diseases; Other Applications
4) By End User: Pharmaceutical And Biotechnology firms; Academic And Research Institutes; Clinical Diagnostic Laboratories
Subsegments:
1) By Kits and Reagents: Deoxyribonucleic Acid Methylation Kits; Histone Modification Kits; Chromatin Accessibility Kits; Bisulfite Conversion Kits; Polymerase Chain Reaction Reagents; Antibodies and Probes; Enzymes and Buffers2) By Software and Services: Data Analysis Software; Bioinformatics Services; Epigenetic Data Interpretation; Cloud-based Data Storage; Custom Assay Development; Validation and Consulting Services
3) By Instruments: Next-Generation Sequencers; Microarray Systems; Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction Instruments; Mass Spectrometry Systems; Imaging Systems; Automation and Liquid Handling Systems
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck KGaA; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; PerkinElmer Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; GeneTex Inc.; Bio-Techne Corporation; Promega Corporation; New England Biolabs Incorporated; Pacific Biosciences of California Inc.; Enzo Biochem Inc.; Diagenode Société Anonyme; Zymo Research Corporation; Active Motif Inc.; ADmit Therapeutics SL; Epigentek Group Inc.; INHERENT Biosciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Epigenetics Diagnostics market report include:- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- GeneTex Inc.
- Bio-Techne Corporation
- Promega Corporation
- New England Biolabs Incorporated
- Pacific Biosciences of California Inc.
- Enzo Biochem Inc.
- Diagenode Société Anonyme
- Zymo Research Corporation
- Active Motif Inc.
- ADmit Therapeutics SL
- Epigentek Group Inc.
- INHERENT Biosciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.29 Billion |
| Forecasted Market Value ( USD | $ 35.17 Billion |
| Compound Annual Growth Rate | 16.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
